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Background
Breast and ovarian cancer are the most frequent causes of
death in women, generating an important problem. A
small proportion of these tumors results from alterations
in cancer susceptibility genes. Two of these genes are
BRCA1 and BRCA2, which are described as hereditary
breast and ovarian cancer genes. BRCA1 mutations have
been identified in 15 to 20% of women with familiar
breast cancer, and in 60 to 80% of women with familiar
breast and ovarian cancer; to date over 500 sequence var-
iants have been reported for this gene. It is estimated that
mutations in BRCA2 cause approximately 35% of heredi-
tary breast cancer cases, besides, is associated with breast
cancer in men, ovarian, pancreas and prostate cancer. Spe-
cific mutations to particular ethnic groups have been
described. There are no known mutations for the Mexican
population. The purposes of this work were to determine
the mutation frequency of BRCA1 and BRCA2 genes in
breast cancer patients under 40 years old or patients with
familiar breast and/or ovarian cancer history, through
DHPLC analysis and, to establish genotype-phenotype
correlations. Those families with mutations will be fol-
lowed-up for an early detection, and will receive genetic
counseling.
Materials and methods
Forty breast and/or ovarian cancer patients were included.
DNA was obtained from peripheral leukocytes, and was
amplified for the 24 exons of BRCA1 using 31 pairs of oli-
gonucleotides, and for the 26 exons of BRCA2 with 39
pairs of primers. The primers were designed to include
each exon flanked by a small portion of the corresponding
introns. The amplifications were analyzed in a DHPLC
(Transgenomics).
Results
We have analyzed the entire BRCA2 gene for the 40
patients, and found 1 polymorphism at exon 4 in 4
patients and 4 different polymorphisms at exon 11 in 24
patients. We identify a patient with a mutation in exon 11
already reported at Breast Cancer International Core
(BIC), which was also present in her father, for this reason
the rest of the family will be analyzed and receive the
appropriate genetic counseling. Regarding BRCA1, we
have completed the amplifications, and we are now per-
forming the DHPLC analysis.
Conclusion
We have found an elevated percentage of patients with
polymorphisms (up to 30%). Until now we have found
only one mutation, which has been reported only three
times in the BIC. It seems that mutations in BRCA2 are not
frequent in our hereditary breast cancer patients.
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